A new study shows just how few Americans have been infected with the deadly pathogen.
Critics say the writing is on the wall—even if they’re holding out hope for scientists to do the right thing.
Scientists say a new antibody approach could both treat and help prevent COVID-19—even if it mutates. But will it arrive before a vaccine?
The United Arab Emirates. Russia. China. Experts say there is plenty of reason to be skeptical.
“If we had the leadership we needed, I’m pretty certain we would have been under 100,000 fatalities—and probably under 50,000 if we had been aggressive from the beginning.”
The vaccine, in Phase 3 trials, was put on hold due to an unspecified adverse reaction in a patient—which means that the science-based vetting process is rigorous and it’s working.
From refrigeration woes to anti-vaxxer sentiment, rushing vaccine safety trials is far from the only way this could go bad.
It’s either a testament to the immune system, or a terrifying sign of limited immunity.
The tests are promising. But this kind of test has also been used to deflate COVID-19 case totals, critics say.